Do analysts rate SPRB or QNTM?

Spruce Biosciences presently has a consensus price target of $176.60, suggesting a potential upside of 232.14%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Spruce Biosciences is more favorable than Quantum Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spruce Biosciences 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SPRB or QNTM more profitable?

Spruce Biosciences' return on equity of -155.40% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Spruce Biosciences N/A -155.40% -101.67% Quantum Biopharma N/A -941.54% -224.41%

Do analysts rate QNTM or INDP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, QNTM or INDP?

Quantum Biopharma is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quantum Biopharma N/A N/A -$26.17M -$8.25 N/A Indaptus Therapeutics N/A N/A -$20.85M -$15.40 N/A

Is QNTM or INDP more profitable?

Quantum Biopharma's return on equity of -941.54% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Quantum Biopharma N/A -941.54% -224.41% Indaptus Therapeutics N/A -1,030.07% -299.69%

Does the media prefer QNTM or INDP?

In the previous week, Quantum Biopharma had 3 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 6 mentions for Quantum Biopharma and 3 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 0.62 beat Quantum Biopharma's score of 0.45 indicating that Indaptus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quantum Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Indaptus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend VTVT or QNTM?

vTv Therapeutics presently has a consensus price target of $53.00, indicating a potential upside of 54.29%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe vTv Therapeutics is more favorable than Quantum Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score vTv Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is VTVT or QNTM more profitable?

vTv Therapeutics' return on equity of 3.96% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets vTv Therapeutics N/A 3.96% 2.86% Quantum Biopharma N/A -941.54% -224.41%

Does the media favor VTVT or QNTM?

In the previous week, Quantum Biopharma had 4 more articles in the media than vTv Therapeutics. MarketBeat recorded 6 mentions for Quantum Biopharma and 2 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 0.63 beat Quantum Biopharma's score of 0.45 indicating that vTv Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment vTv Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quantum Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend QNTM or THAR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, QNTM or THAR?

Tharimmune is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quantum Biopharma N/A N/A -$26.17M -$8.25 N/A Tharimmune N/A N/A -$12.20M -$3.99 N/A

Is QNTM or THAR more profitable?

Tharimmune's return on equity of -588.45% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Quantum Biopharma N/A -941.54% -224.41% Tharimmune N/A -588.45% -264.41%

Do analysts prefer QNTM or RANI?

Rani Therapeutics has a consensus price target of $8.75, indicating a potential upside of 873.74%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rani Therapeutics is more favorable than Quantum Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quantum Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Rani Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60

Is QNTM or RANI more profitable?

Rani Therapeutics' return on equity of -206.46% beat Quantum Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Quantum Biopharma N/A -941.54% -224.41% Rani Therapeutics N/A -206.46% -83.95%

Does the media prefer QNTM or RANI?

In the previous week, Rani Therapeutics had 3 more articles in the media than Quantum Biopharma. MarketBeat recorded 9 mentions for Rani Therapeutics and 6 mentions for Quantum Biopharma. Rani Therapeutics' average media sentiment score of 1.06 beat Quantum Biopharma's score of 0.45 indicating that Rani Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Quantum Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rani Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Quantum Biopharma (QNTM) Competitors

$4.48 -0.40 (-8.20%)

Closing price 04:00 PM Eastern

Extended Trading

$4.51 +0.03 (+0.76%)

As of 07:59 PM Eastern

Compare

QNTM vs. SPRB, INDP, VTVT, THAR, and RANI

Should you buy Quantum Biopharma stock or one of its competitors? MarketBeat compares Quantum Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Quantum Biopharma include Spruce Biosciences (SPRB), Indaptus Therapeutics (INDP), vTv Therapeutics (VTVT), Tharimmune (THAR), and Rani Therapeutics (RANI). These companies are all part of the "pharmaceutical products" industry.

How does Quantum Biopharma compare to Spruce Biosciences?

Spruce Biosciences (NASDAQ:SPRB) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

In the previous week, Spruce Biosciences had 4 more articles in the media than Quantum Biopharma. MarketBeat recorded 10 mentions for Spruce Biosciences and 6 mentions for Quantum Biopharma. Spruce Biosciences' average media sentiment score of 0.96 beat Quantum Biopharma's score of 0.45 indicating that Spruce Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Spruce Biosciences	Positive
Quantum Biopharma	Neutral

91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are held by institutional investors. 4.3% of Spruce Biosciences shares are held by insiders. Comparatively, 8.5% of Quantum Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Spruce Biosciences presently has a consensus price target of $176.60, suggesting a potential upside of 232.14%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Spruce Biosciences is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Spruce Biosciences' return on equity of -155.40% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-155.40%	-101.67%
Quantum Biopharma	N/A	-941.54%	-224.41%

Quantum Biopharma has lower revenue, but higher earnings than Spruce Biosciences. Spruce Biosciences is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91M	29.78	-$38.97M	-$36.60	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A

Spruce Biosciences has a beta of 3.11, indicating that its stock price is 211% more volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.36, indicating that its stock price is 64% less volatile than the broader market.

Summary

Spruce Biosciences beats Quantum Biopharma on 10 of the 14 factors compared between the two stocks.

How does Quantum Biopharma compare to Indaptus Therapeutics?

Quantum Biopharma (NASDAQ:QNTM) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

In the previous week, Quantum Biopharma had 3 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 6 mentions for Quantum Biopharma and 3 mentions for Indaptus Therapeutics. Indaptus Therapeutics' average media sentiment score of 0.62 beat Quantum Biopharma's score of 0.45 indicating that Indaptus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quantum Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Indaptus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quantum Biopharma has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.25, suggesting that its stock price is 25% more volatile than the broader market.

Quantum Biopharma's return on equity of -941.54% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-941.54%	-224.41%
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

1.2% of Quantum Biopharma shares are held by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are held by institutional investors. 8.5% of Quantum Biopharma shares are held by insiders. Comparatively, 23.6% of Indaptus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Quantum Biopharma is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A

Summary

Indaptus Therapeutics beats Quantum Biopharma on 6 of the 10 factors compared between the two stocks.

How does Quantum Biopharma compare to vTv Therapeutics?

vTv Therapeutics (NASDAQ:VTVT) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

In the previous week, Quantum Biopharma had 4 more articles in the media than vTv Therapeutics. MarketBeat recorded 6 mentions for Quantum Biopharma and 2 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 0.63 beat Quantum Biopharma's score of 0.45 indicating that vTv Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
vTv Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quantum Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

vTv Therapeutics presently has a consensus price target of $53.00, indicating a potential upside of 54.29%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe vTv Therapeutics is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are held by institutional investors. 6.0% of vTv Therapeutics shares are held by insiders. Comparatively, 8.5% of Quantum Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

vTv Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.36, indicating that its share price is 64% less volatile than the broader market.

vTv Therapeutics' return on equity of 3.96% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	3.96%	2.86%
Quantum Biopharma	N/A	-941.54%	-224.41%

Quantum Biopharma has lower revenue, but higher earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02M	132.69	-$26.97M	-$0.93	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A

Summary

vTv Therapeutics beats Quantum Biopharma on 10 of the 15 factors compared between the two stocks.

How does Quantum Biopharma compare to Tharimmune?

Quantum Biopharma (NASDAQ:QNTM) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

Tharimmune's return on equity of -588.45% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-941.54%	-224.41%
Tharimmune	N/A	-588.45%	-264.41%

Tharimmune is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A

Quantum Biopharma has a beta of 0.36, indicating that its share price is 64% less volatile than the broader market. Comparatively, Tharimmune has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market.

In the previous week, Quantum Biopharma had 6 more articles in the media than Tharimmune. MarketBeat recorded 6 mentions for Quantum Biopharma and 0 mentions for Tharimmune. Quantum Biopharma's average media sentiment score of 0.45 beat Tharimmune's score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Quantum Biopharma	Neutral
Tharimmune	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

1.2% of Quantum Biopharma shares are held by institutional investors. Comparatively, 1.2% of Tharimmune shares are held by institutional investors. 8.5% of Quantum Biopharma shares are held by company insiders. Comparatively, 6.7% of Tharimmune shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Quantum Biopharma beats Tharimmune on 6 of the 10 factors compared between the two stocks.

How does Quantum Biopharma compare to Rani Therapeutics?

Quantum Biopharma (NASDAQ:QNTM) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

In the previous week, Rani Therapeutics had 3 more articles in the media than Quantum Biopharma. MarketBeat recorded 9 mentions for Rani Therapeutics and 6 mentions for Quantum Biopharma. Rani Therapeutics' average media sentiment score of 1.06 beat Quantum Biopharma's score of 0.45 indicating that Rani Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quantum Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rani Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quantum Biopharma has higher earnings, but lower revenue than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A
Rani Therapeutics	$1.63M	68.29	-$29.67M	-$0.41	N/A

Rani Therapeutics' return on equity of -206.46% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum Biopharma	N/A	-941.54%	-224.41%
Rani Therapeutics	N/A	-206.46%	-83.95%

Rani Therapeutics has a consensus price target of $8.75, indicating a potential upside of 873.74%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rani Therapeutics is more favorable than Quantum Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Quantum Biopharma has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

1.2% of Quantum Biopharma shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by insiders. Comparatively, 26.7% of Rani Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Rani Therapeutics beats Quantum Biopharma on 12 of the 14 factors compared between the two stocks.

Get Quantum Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QNTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QNTM vs. The Competition

Export

Metric	Quantum Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$17.11M	$3.34B	$6.44B	$12.46B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-0.54	18.78	23.87	24.36
Price / Sales	N/A	320.80	521.52	117.01
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	3.34	6.80	9.99	6.73
Net Income	-$26.17M	$24.09M	$3.56B	$337.03M
7 Day Performance	-36.18%	-2.56%	-0.89%	0.09%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	-69.17%	48.90%	28.76%	33.98%

Quantum Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QNTM Quantum Biopharma	0.5503 of 5 stars	$4.48 -8.2%	N/A	-68.4%	$17.11M	N/A	N/A	N/A	Gap Down
SPRB Spruce Biosciences	2.719 of 5 stars	$51.81 +1.4%	$186.60 +260.2%	+906.2%	$140.57M	N/A	N/A	20	Analyst Forecast Analyst Revision Gap Up
INDP Indaptus Therapeutics	1.0438 of 5 stars	$1.11 -9.0%	N/A	-77.3%	$138.16M	N/A	N/A	6	News Coverage Gap Down Trading Halted
VTVT vTv Therapeutics	2.7194 of 5 stars	$33.16 -3.6%	$53.00 +59.8%	+102.1%	$135.52M	$36.84M	N/A	9
THAR Tharimmune	N/A	$3.52 +5.1%	N/A	+51.4%	$132.81M	N/A	N/A	2	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QNTM) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quantum Biopharma (QNTM) Competitors

QNTM vs. SPRB, INDP, VTVT, THAR, and RANI

How does Quantum Biopharma compare to Spruce Biosciences?

Summary

How does Quantum Biopharma compare to Indaptus Therapeutics?

Summary

How does Quantum Biopharma compare to vTv Therapeutics?

Summary

How does Quantum Biopharma compare to Tharimmune?

Summary

How does Quantum Biopharma compare to Rani Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM vs. The Competition

Quantum Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quantum Biopharma (QNTM) Competitors

QNTM vs. SPRB, INDP, VTVT, THAR, and RANI

How does Quantum Biopharma compare to Spruce Biosciences?

Does the media favor SPRB or QNTM?

Do institutionals and insiders hold more shares of SPRB or QNTM?

Do analysts rate SPRB or QNTM?

Is SPRB or QNTM more profitable?

Which has higher valuation & earnings, SPRB or QNTM?

Which has more volatility & risk, SPRB or QNTM?

Summary

How does Quantum Biopharma compare to Indaptus Therapeutics?

Does the media prefer QNTM or INDP?

Which has more risk and volatility, QNTM or INDP?

Is QNTM or INDP more profitable?

Do analysts rate QNTM or INDP?

Do insiders and institutionals believe in QNTM or INDP?

Which has better earnings and valuation, QNTM or INDP?

Summary

How does Quantum Biopharma compare to vTv Therapeutics?

Does the media favor VTVT or QNTM?

Do analysts recommend VTVT or QNTM?

Do insiders & institutionals hold more shares of VTVT or QNTM?

Which has more risk & volatility, VTVT or QNTM?

Is VTVT or QNTM more profitable?

Which has better valuation and earnings, VTVT or QNTM?

Summary

How does Quantum Biopharma compare to Tharimmune?

Is QNTM or THAR more profitable?

Which has preferable earnings & valuation, QNTM or THAR?

Which has more volatility and risk, QNTM or THAR?

Does the media refer more to QNTM or THAR?

Do analysts recommend QNTM or THAR?

Do insiders & institutionals have more ownership in QNTM or THAR?

Summary

How does Quantum Biopharma compare to Rani Therapeutics?

Does the media prefer QNTM or RANI?

Which has preferable earnings and valuation, QNTM or RANI?

Is QNTM or RANI more profitable?

Do analysts prefer QNTM or RANI?

Which has more risk & volatility, QNTM or RANI?

Do institutionals and insiders believe in QNTM or RANI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNTM vs. The Competition

Quantum Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools